KLRK1 and neoplasm: NKG2D can compensate for loss of CD28 signaling to boost cytotoxicity via granzyme B production.NKG2D-mediated cytotoxicity requires prior TCR engagementNKG2D+ CD8+ T cells direct anti-tumor responses to MHC-I deficient tumors